Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Forschungsprojekte
Ergebnisse pro Seite:
100
2023 - 2026
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer- Univ.-Prof. Dr. med. Marcus Schmidt,
- Dr. Katrin Almstedt
2022 - 2030
AGO-TR" Prävalenz von somatischen und Keimbahnmutationen bei Patientinnen mit primärem oder rezidiviertem Endometriumkarzinom- Univ.-Prof. Dr. Annette Hasenburg,
- Dr. Ina Shehaj
2022 - 2027
Analysis of antibody responses against tumor-derived neo-antigens in triple-negative breast cancer (TNBC)- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2022 - 2027
Characterization of the immunoglobulin repertoire of tumor-infiltrating plasma cells and correlation of factors within the plasma with prognosis in early breast cancer- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2022 - 2027
Isolation and characterization of tumor stem cells utilizing ascites or pleural effusions- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2022 - 2029
Process optimization for the identification of patient-specific neo-antigens in breast cancer patients- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2022 - 2029
Concordance of biomarkers between primary breast tumors and matched distant metastases- Univ.-Prof. Dr. Marcus Schmidt,
- Dr. Kathrin Stewen,
- PD Dr. Katrin Almstedt
2022 - 2027
Prognostic role of LAG-3 in early breast cancer- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Anne-Sophie Heimes
2021 - 2030
TEDOVA Randomisierte Phase II Studie zum Vergleich eines neo-epitope basierten Vakzin OSE2101 (TEDOPI®) +/- anti-PD1 (Pembrolizumab) versus supportiver Therapie/Beobachtung in der Erhaltungstherapie bei Patientinnen mit platin-sensitiven Ovarialkarzinom-Rezidiv und kontrollierter Erkrankung nach platinbasierter Chemotherapie.- Dr. Anne-Sophie Heimes,
- Univ.-Prof. Dr. Annette Hasenburg
2020 - 2025
Concordance of PD-L1 expression in breast carcinoma between primarius and metastasis- Univ.-Prof. Dr. Marcus Schmidt,
- Dr. Kathrin Stewen
2018 - 2025
AGO Ovar 22: A Phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin and Bevacizumab to patients with newly diagnosed Stage III or Stage IV ovarian, Fallopian Tube or primary Peritoneal Cancer- Univ.-Prof. Dr. Annette Hasenburg,
- Dr. Marco Battista
2018
AGO Ovar 2.29 Atezolizumab in Kombination mit Bevacizumab und Chemotherapie versus Bevacizumab und Chemotherapie beim rezidivierenden Ovarialkarzinom - eine randomisierte Phase III Studie- Dr. Katrin Almstedt,
- Univ.-Prof. Dr. Annette Hasenburg
2017 - 2019
Histone deacetylase 6 as a new target in the therapy of ovarian cancer- Dr. Ines Breuksch,
- Prof. Dr. Walburgis Brenner,
- Univ.-Prof. Dr. Oliver Krämer
2017 - 2020
Impact of the Calcium sensing receptor on the progression of ovarian cancer and endometriosis- Prof. Dr. Walburgis Brenner
2017 - 2020
Impact of the tissue factor in the integration of a pre-vascularized in vitro mucosa equivalent- Dr. Sandra Nezi,
- Dr. Martin Heller,
- Prof. Dr. Walburgis Brenner
2017 - 2020
Mütterliche Präferenzen bei der Entscheidungsfindung für Frühgeborene im Grenzbereich der Lebensfähigkeit (PREFAB-Studie)- Dr. André Kidszun,
- Univ.-Prof. Dr. Eva Mildenberger
2017 - 2020
MUC1 variant as a potential target in the therapy of triple-negative breast cancer (TNBC)- Dr. Anne-Sophie Heimes
2016 - 2020
Identification and characterization of exosomal miRNA‘s in liquid biopsies as marker in breast cancer- Dr. Roxana Schwab,
- Prof. Dr. Walburgis Brenner
2016 - 2020
Analysis of antibody responses against tumor-derived neo-antigens in triple-negative breast cancer (TNBC)- Dr. Anne-Sophie Heimes,
- Univ.-Prof. Dr. Marcus Schmidt,
- Prof. Dr. Walburgis Brenner
2016 - 2025
DESIREE – eine multizentrische, randomisierte doppelblinde, Phase-II-Studie zum Vergleiche der Verträglichkeit bei- Univ.-Prof. Dr. Marcus Schmidt,
- Dr. Marco Battista
2015 - 2018
Identifizierung diagnostischer Marker zur verbesserten Therapieentscheidung beim nodal-negativen Mammakarziniom- Univ.-Prof. Dr. Marcus Schmidt,
- Univ.-Prof. Dr. Wilfried Roth,
- Univ.-Prof. Dr. Ugur Sahin
2015 - 2020
VinoMetro - Phase II study of metronomic treatment with daily oral vinorelbine in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy- Univ.-Prof. Dr. Marcus Schmidt
2015 - 2020
Development and characterization of an in vitro generated pre-vascularized mucosa equivalent- Prof. Dr. Walburgis Brenner
2015 - 2020
Role of the tumor suppressor PTEN and its splice variant PTENdelta in tumorigenesis and metastasis- Prof. Dr. Walburgis Brenner
2014 - 2016
Prozessoptimierung zur Identifikation von patienten-spezifischen Antigen-Expressionsprofilen und individuellen Tumormutationen bei Brustkrebspatientinnen- Univ.-Prof. Dr. Marcus Schmidt,
- Univ.-Prof. Dr. Ugur Sahin
2014 - 2018
Energy metabolism in ovarian cancer- Dr. Marco Johannes Battista,
- PD Dr. Stefan Walenta,
- Univ.-Prof. Dr. Wolfgang Müller-Klieser,
- Univ.-Prof. Dr. Marcus Schmidt,
- Univ.-Prof. Dr. Annette Hasenburg
2014 - 2016
Isolation und Charakterisierung von Tumorstammzellen aus Pleura-/Aszitespunktaten- Univ.-Prof. Dr. Marcus Schmidt,
- PD Dr. Marcus-Alexander Wörns,
- Univ.-Prof. Dr. Ugur Sahin
2013 - 2016
PASSOS: Personalized estimation of long-term outcomes after radiation exposure and orientations help for radiation help in medicine (BMBF)- Univ.-Prof. Dr. Maria Blettner,
- PD Dr. Markus Schmidt,
- Univ.-Prof. Dr. Heinz Schmidberger
2012 - 2025
Identification of prognostic and predictive factors in breast cancer using Next-Generation Sequencing (NGS)- PD Dr. Marcus Schmidt,
- Univ.-Prof. Dr. Ugur Sahin,
- Dr. Castle John
2011 - 2013
Geburtsmodus Frühgeborener eines Schätzgewichtes < 1500g- Univ.-Prof. Dr. Eva Mildenberger,
- Anne-Jule Fuchs